Patents by Inventor Jonathan Serody

Jonathan Serody has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CD30-POSITIVE CANCER
    Publication number: 20230263890
    Abstract: Methods for treating a CD30-positive cancer in a subject are disclosed, wherein the methods comprise administering a lymphodepleting chemotherapy and CD30-specific chimeric antigen receptor (CAR)-expressing cells.
    Type: Application
    Filed: June 4, 2021
    Publication date: August 24, 2023
    Applicants: Tessa Therapeutics Ltd., The University of North Carolina at Chapel Hill
    Inventors: Aung Myo, Ivan David Horak, Jonathan Serody, Gianpietro Dotti, Barbara Savoldo
  • USE OF AGONISTS TO AUGMENT CAR T FUNCTION IN SOLID TUMORS
    Publication number: 20230131219
    Abstract: Disclosed herein is a chimeric antigen receptor T cell therapy for treating patients having a cancer, such as a cancer having one or more solid tumors.
    Type: Application
    Filed: November 9, 2020
    Publication date: April 27, 2023
    Inventors: Jonathan Serody, Nicholas P. Restifo, Nuo Xu
  • Compositions and methods for preventing and treating graft versus host disease
    Patent number: 11471517
    Abstract: ILC2 cells play a role in the pathogenesis of graft versus host disease (GvHD) and idiopathic pneumonia syndrome (IPS), both conditions associated with allogeneic stem cell transplantation. Infusion of IL-33 activated ILC2 cells into patients with ongoing GvHD or IPS, or prior to onset of GvHD or IPS in susceptible patients, substantially ameliorates the disease and improves survival.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: October 18, 2022
    Assignees: The University of North Carolina at Chapel Hill, Regents of the University of Minnesota
    Inventors: Jonathan Serody, James Coghill, Danny Bruce, Bruce Blazar, Heather Stefanski, Benjamin Vincent
  • METHODS FOR SUBTYPING OF LUNG SQUAMOUS CELL CARCINOMA
    Publication number: 20210340631
    Abstract: Methods and compositions are provided for determining a subtype of lung squamous cell carcinoma (SQ) of an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for lung squamous cell carcinoma. Also provided herein are methods and compositions for determining the response of an individual with a squamous cell carcinoma subtype to a therapy such as immunotherapy.
    Type: Application
    Filed: May 18, 2021
    Publication date: November 4, 2021
    Inventors: Hawazin FARUKI, Myla LAI-GOLDMAN, Greg MAYHEW, Jonathan SERODY, Charles PEROU, David Neil HAYES
  • METHODS FOR SUBTYPING OF LUNG ADENOCARCINOMA
    Publication number: 20210222254
    Abstract: Methods and compositions are provided for determining a subtype of lung adenocarcinoma (AD) of an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for lung adenocarcinoma. Also provided herein are methods and compositions for determining the response of an individual with an adenocarcinoma subtype to a therapy such as immunotherapy.
    Type: Application
    Filed: January 22, 2021
    Publication date: July 22, 2021
    Inventors: Hawazin FARUKI, Myla LAI-GOLDMAN, Greg MAYHEW, Jonathan SERODY, Charles PEROU, David Neil HAYES
  • Methods for subtyping of lung squamous cell carcinoma
    Patent number: 11041214
    Abstract: Methods and compositions are provided for determining a subtype of lung squamous cell carcinoma (SQ) of an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for lung squamous cell carcinoma. Also provided herein are methods and compositions for determining the response of an individual with a squamous cell carcinoma subtype to a therapy such as immunotherapy.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: June 22, 2021
    Assignees: GeneCentric Therapeutics, Inc., The University of North Carolina at Chapel Hill
    Inventors: Hawazin Faruki, Myla Lai-Goldman, Greg Mayhew, Jonathan Serody, Charles Perou, David Neil Hayes
  • Methods for subtyping of lung adenocarcinoma
    Patent number: 10934595
    Abstract: Methods and compositions are provided for determining a subtype of lung adenocarcinoma (AD) of an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for lung adenocarcinoma. Also provided herein are methods and compositions for determining the response of an individual with an adenocarcinoma subtype to a therapy such as immunotherapy.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: March 2, 2021
    Assignees: GeneCentric Therapeutics, Inc., The University of North Carolina at Chapel Hill
    Inventors: Hawazin Faruki, Myla Lai-Goldman, Greg Mayhew, Jonathan Serody, Charles Perou, David Neil Hayes
  • COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING GRAFT VERSUS HOST DISEASE
    Publication number: 20200155656
    Abstract: ILC2 cells play a role in the pathogenesis of graft versus host disease (GvHD) and idiopathic pneumonia syndrome (IPS), both conditions associated with allogeneic stem cell transplantation. Infusion of IL-33 activated ILC2 cells into patients with ongoing GvHD or IPS, or prior to onset of GvHD or IPS in susceptible patients, substantially ameliorates the disease and improves survival.
    Type: Application
    Filed: October 10, 2019
    Publication date: May 21, 2020
    Inventors: Jonathan Serody, James Coghill, Danny Bruce, Bruce Blazar, Heather Stefanski, Benjamin Vincent
  • METHODS FOR SUBTYPING OF LUNG ADENOCARCINOMA
    Publication number: 20190338365
    Abstract: Methods and compositions are provided for determining a subtype of lung adenocarcinoma (AD) of an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for lung adenocarcinoma. Also provided herein are methods and compositions for determining the response of an individual with an adenocarcinoma subtype to a therapy such as immunotherapy.
    Type: Application
    Filed: May 17, 2017
    Publication date: November 7, 2019
    Inventors: Hawazin FARUKI, Myla LAI-GOLDMAN, Greg MAYHEW, Jonathan SERODY, Charles PEROU, David Neil HAYES
  • METHODS FOR SUBTYPING OF LUNG SQUAMOUS CELL CARCINOMA
    Publication number: 20190338366
    Abstract: Methods and compositions are provided for determining a subtype of lung squamous cell carcinoma (SQ) of an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for lung squamous cell carcinoma. Also provided herein are methods and compositions for determining the response of an individual with a squamous cell carcinoma subtype to a therapy such as immunotherapy.
    Type: Application
    Filed: May 17, 2017
    Publication date: November 7, 2019
    Inventors: Hawazin FARUKI, Myla LAI-GOLDMAN, Greg MAYHEW, Jonathan SERODY, Charles PEROU, David Neil HAYES
  • COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING GRAFT VERSUS HOST DISEASE
    Publication number: 20170360907
    Abstract: ILC2 cells play a role in the pathogenesis of graft versus host disease (GvHD) and idiopathic pneumonia syndrome (IPS), both conditions associated with allogeneic stem cell transplantation. Infusion of IL-33 activated ILC2 cells into patients with ongoing GvHD or IPS, or prior to onset of GvHD or IPS in susceptible patients, substantially ameliorates the disease and improves survival.
    Type: Application
    Filed: December 4, 2015
    Publication date: December 21, 2017
    Inventors: Jonathan Serody, James Coghill, Danny Bruce, Bruce Blazar, Heather Stefanski, Benjamin Vincent
  • Methods for treating or preventing GVHD
    Publication number: 20050208036
    Abstract: Methods are provided for administering alloreactive T cells to transplant recipients such that the risk of graft-versus-host disease is reduced.
    Type: Application
    Filed: January 10, 2005
    Publication date: September 22, 2005
    Inventors: Bruce Blazar, Matthew O'Shaughnessy, Christine Vogtenhuber, Jonathan Serody, Albert Baldwin